When Denial Becomes the System: Jace Yawnick

The system does not fail when it denies care. It performs exactly as designed.

That conclusion unsettles people because it removes the comfort of blaming error. Most stakeholders prefer to believe that coverage denials, delayed diagnostics, and uneven access reflect breakdowns in execution. The data, the incentives, and lived experience point elsewhere. The American healthcare system optimizes for cost control within fragmented risk pools. It protects balance sheets first and clinical outcomes second. That ordering produces predictable results.

Start with the basic structure. Employer sponsored insurance covers roughly 160,000,000 Americans. Each employer selects a plan with a defined network, a defined formulary, and a defined approach to utilization management. Insurers price these plans based on expected claims, administrative overhead, and margin targets. Employers choose based on premiums, not clinical nuance. Employees rarely evaluate coverage until illness forces the issue.

That structure creates a roulette dynamic. A 24 year old who accepts a job at Company A inherits a different set of clinical options than a peer at Company B. Both may receive a cancer diagnosis. One gains access to comprehensive oncology centers, timely imaging, and broad drug coverage. The other navigates narrower networks, step therapy, and prior authorization hurdles. The difference reflects contract design, not medical need.

Insurers defend this system with a rational argument. Healthcare spending reached $4,500,000,000,000 in 2022. Without controls, costs would rise faster. Prior authorization, network management, and formulary restrictions serve as tools to prevent overuse and reduce unnecessary care. In theory, these mechanisms align resources with evidence based practice.

In practice, they shift risk onto patients and providers in ways that undermine both clinical outcomes and economic efficiency.

Prior authorization illustrates the point. Insurers require approval before certain tests, procedures, or medications. The stated goal centers on ensuring appropriate use. The operational reality centers on delay and denial as cost containment strategies. A physician submits documentation. A reviewer, who may not share the same specialty, evaluates the request against plan criteria. The insurer approves, delays, or denies.

Each outcome carries consequences. Approval allows care to proceed. Delay introduces uncertainty, administrative burden, and in many cases clinical deterioration. Denial forces appeals, alternative treatments, or abandonment of care. The system counts on attrition. Some patients lack the time, knowledge, or support to navigate appeals. Providers face finite administrative capacity. Each denied or delayed service reduces immediate spending.

This dynamic does not reflect malice. It reflects incentives. Insurers operate under medical loss ratio requirements that mandate a minimum percentage of premium dollars spent on care. They still retain flexibility in timing and allocation. Delaying or denying high cost interventions improves short term financial performance. The longer the delay, the more likely patients will exit the system through resolution, progression, or mortality. That outcome reduces long term liability.

Cancer care exposes the tension between cost control and patient protection with unusual clarity. Oncology has seen rapid advances in diagnostics and therapeutics. Immunotherapies, targeted agents, and precision medicine approaches have improved survival for many cancers. These innovations come with high price tags. A single course of treatment can exceed $150,000. Diagnostic imaging such as PET scans plays a critical role in staging, monitoring, and detecting recurrence.

When an insurer denies a PET scan for a patient in remission surveillance, it applies plan criteria to determine medical necessity. The patient experiences that decision as an existential threat. The clinical rationale may support the scan. The financial incentive may support denial. Both perspectives can coexist within the same system.

The broader market compounds the issue. Pharmaceutical companies price oncology drugs based on value frameworks, competitive positioning, and expected market size. Hospitals negotiate reimbursement rates with insurers. Providers invest in infrastructure and staff based on anticipated revenue streams. Each actor responds to its own incentive set. The system lacks a unifying mechanism that aligns all parties around long term patient outcomes.

This fragmentation produces inefficiencies that increase total cost while degrading patient experience. Administrative complexity consumes an estimated $300,000,000,000 annually. Providers employ staff to manage billing, coding, and authorization processes. Insurers employ staff to review and adjudicate claims. Patients spend time navigating a system that requires specialized knowledge to access basic services.

From a market perspective, this represents deadweight loss. Resources flow toward administrative functions that do not directly improve health outcomes. At the same time, barriers to timely care can lead to disease progression that requires more intensive and expensive interventions later. A delayed diagnosis or denied scan can result in advanced disease that costs more to treat and carries worse outcomes.

The system claims to promote value based care. It often rewards volume reduction in the short term while ignoring downstream costs. That misalignment creates a false economy.

Mental health care provides a parallel example. Patients undergoing cancer treatment face significant psychological stress. Depression, anxiety, and post treatment adjustment issues are common. Evidence shows that integrated mental health support can improve adherence, quality of life, and in some cases clinical outcomes. Coverage for these services remains inconsistent. Many plans offer limited networks, high out of pocket costs, or administrative barriers.

The system underinvests in mental health because the financial return is diffuse and delayed. Insurers may not capture the full benefit of improved outcomes if patients change plans. Employers may not see immediate productivity gains. Patients bear the cost in reduced quality of life and increased risk of complications.

Critics often frame these issues as moral failures. That framing obscures the underlying mechanics. The system behaves rationally within its constraints. Each actor optimizes for its own objectives. The misalignment arises because those objectives do not fully incorporate patient welfare over the long term.

Reform efforts frequently focus on expanding coverage or increasing funding. These approaches address access but do not resolve incentive misalignment. A system that pays for more care without changing how decisions are made will continue to produce inconsistent outcomes.

Effective reform requires realigning incentives across stakeholders.

First, reimbursement models must reward outcomes over process. Value based payment structures can align provider incentives with patient outcomes. These models need robust risk adjustment and longitudinal accountability to avoid penalizing providers who treat complex patients. Bundled payments for oncology care represent one approach. They can encourage coordination, reduce unnecessary services, and focus attention on outcomes.

Second, prior authorization processes require redesign. Evidence based guidelines should drive decisions, with transparent criteria and accountability for timeliness. Independent review mechanisms can reduce conflicts of interest. Technology can streamline data exchange between providers and payers, reducing administrative burden. Financial incentives should penalize unnecessary delays that lead to worse outcomes.

Third, coverage should follow the patient, not the employer. Portable benefits or public options can reduce the variability introduced by employer based plans. Patients with serious conditions should not face different standards of care based on employment status. A more uniform baseline of coverage would reduce inequities and improve system efficiency.

Fourth, investment in mental health must reflect its impact on overall outcomes. Integrating behavioral health into oncology care can improve adherence and reduce complications. Payment models should support this integration. Employers and insurers can benefit from reduced long term costs associated with better managed conditions.

Fifth, transparency in pricing and outcomes can support better decision making. Patients, employers, and policymakers need access to data that reflects true cost and quality. This information can drive competition and accountability.

Institutional defenses will emphasize complexity. Healthcare involves diverse conditions, evolving science, and varying patient needs. No single model can address every scenario. That argument holds merit. It does not justify maintaining incentives that systematically disadvantage patients.

Another defense will point to cost containment. Without controls, spending would increase. This argument assumes that current controls represent the best available option. Evidence suggests otherwise. Administrative complexity and delayed care increase total cost. Aligning incentives with outcomes can reduce waste while improving care.

A final defense will highlight innovation. The United States leads in medical research and drug development. The system supports risk taking and capital investment. This strength coexists with access challenges. Innovation that patients cannot access does not fulfill its potential. Aligning coverage with evidence based use can support both innovation and patient protection.

The system performs as designed. It allocates resources based on financial incentives that prioritize short term cost control. Patients experience the consequences when those incentives conflict with clinical need.

Realignment requires deliberate action from policymakers, payers, providers, and employers. Each must accept trade offs. Insurers may face tighter margins in exchange for more predictable long term costs. Providers may need to adapt to new payment models. Employers may need to invest more in comprehensive coverage. Policymakers must create frameworks that support these changes.

The cost of inaction is measurable. Delayed diagnoses, inconsistent access, and untreated mental health issues lead to worse outcomes and higher long term spending. The system will continue to produce these results as long as current incentives remain in place.

The question is not whether the system can change. It has evolved before. The question is whether stakeholders will align incentives in a way that values patient outcomes as a primary objective rather than a secondary effect.

Patients do not need a system that promises excellence. They need one that delivers it consistently.